Related Experiment Video
Updated: Jun 20, 2026

The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
Published on: August 2, 2017
Hemostasis in Pre-Eclamptic Women and Their Offspring: Current Knowledge and Hemostasis Assessment with Viscoelastic
Christos-Georgios Kontovazainitis1, Dimitra Gialamprinou1, Theodoros Theodoridis2
12nd Neonatal Department and Neonatal Intensive Care Unit (NICU), "Papageorgiou" University Hospital, Aristotle University of Thessaloniki, 56403 Thessaloniki, Greece.
Insights
Pre-eclampsia disrupts normal blood clotting, causing hypercoagulability. Viscoelastic tests like TEG/ROTEM show this excessive clotting, aiding in monitoring and predicting pre-eclampsia severity.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Perinatology
Background:
- Pre-eclampsia (PE) is a serious pregnancy complication affecting maternal and neonatal health.
- PE disrupts the normal hypercoagulable state of pregnancy, leading to abnormal blood clotting and fibrinolysis.
- Conventional coagulation tests (CCTs) are insufficient for monitoring hemostatic changes in PE.
Purpose of the Study:
- To review hemostasis in pre-eclampsia compared to normal pregnancy.
- To explore maternal PE's impact on neonatal hemostasis.
- To discuss the utility of viscoelastic tests (TEG/ROTEM) for assessing and monitoring PE-associated hemostatic alterations.
Main Methods:
- This is a narrative review summarizing current knowledge.
- Focuses on comparing hemostasis in PE versus healthy gestation.
- Emphasizes the role of thromboelastography (TEG) and thromboelastometry (ROTEM) in PE.
Main Results:
- TEG/ROTEM reveal excessive hypercoagulability in PE, correlating with disease severity.
- PE is characterized by the formation of higher-stability fibrin clots compared to normal pregnancy.
- TEG/ROTEM parameters show potential as monitoring and predictive markers for PE.
Conclusions:
- Viscoelastic testing (TEG/ROTEM) offers a valuable tool for assessing PE-related hemostatic changes.
- TEG/ROTEM can reflect PE severity and may aid in disease monitoring and prediction.
- Further consideration of TEG/ROTEM in PE management is warranted due to CCT limitations.
Abstract:
Pre-eclampsia (PE) is a placenta-mediated disease and remains a major cause of maternal and neonatal mortality and morbidity. As PE develops, normal pregnancy's hypercoagulable balance is disrupted, leading to platelet hyperactivation, excessive pathological hypercoagulability, and perturbed fibrinolysis. This narrative review aims to summarize the current knowledge regarding hemostasis in PE compared with healthy gestation and the potential effects of maternal PE on neonatal hemostasis. Finally, it aims to discuss hemostasis assessments for normal pregnancies and PE, emphasizing the role of viscoelastic tests, namely, thromboelastography (TEG) and thromboelastometry (ROTEM), for monitoring PE-associated hemostatic alterations. The use of TEG/ROTEM for assessing the hemostatic profile of PE women has been little considered, even though conventional coagulation tests (CCTs) have not helped to monitor hemostasis in this population. Compared with normal pregnancy, TEG/ROTEM in PE reveals an excessive hypercoagulability analogous with the severity of the disease, characterized by higher-stability fibrin clots. The TEG/ROTEM parameters can reflect PE severity and may be used for monitoring and as predictive markers for the disease.
Related Concept Videos
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Vascular Spasm
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Venous Thrombosis IV: Nursing Management

